ARVANIL (cas 128007-31-8) inhibits T lymphocyte activation and ameliorates autoimmune encephalomyelitis

Add time:08/24/2019    Source:sciencedirect.com

This study examined the immunomodulatory effect of ARVANIL (cas 128007-31-8), a synthetic capsaicin–anandamide hybrid. Arvanil inhibits lymphocyte proliferation and IFN-γ production. The phenotype of activated CD4 + T cells treated with arvanil shows a down-regulation of T cell activation markers such as CD25, HLA-DR and CD134/OX40. Arvanil and anandamide do not induce apoptosis on CD4 + T cells. Arvanil blocks the G1/S phase transition of the cell cycle in stimulated peripheral blood mononuclear cells, inducing activation of p21waf-1/cip-1 and phosphorylation of Akt/PKB. In vivo, arvanil ameliorates experimental autoimmune encephalomyelitis in the SJL/J mouse. Our findings have relevance for the use of arvanil and related compounds as a novel immunotherapeutic approach in the treatment of multiple sclerosis.

We also recommend Trading Suppliers and Manufacturers of ARVANIL (cas 128007-31-8). Pls Click Website Link as below: cas 128007-31-8 suppliers

Prev:Role of VR1 and CB1 receptors in modelling of cardio-respiratory response to ARVANIL (cas 128007-31-8), an endocannabinoid and vanilloid hybrid, in rats
Next:Short CommunicationARVANIL (cas 128007-31-8), a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's disease)